FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048930036> ?p ?o ?g. }

• W3048930036 abstract "Abstract Background The role of omega-3 polyunsaturated fatty acids (n-3PUFA), and the potential impact of n-3PUFA supplementation, in the treatment and management of type 1 diabetes (T1D) remains unclear and controversial. Therefore, this study aimed to examine the efficacy of daily high-dose-bolus n-3PUFA supplementation on vascular health, glycaemic control, and metabolic parameters in subjects with T1D. Methods Twenty-seven adults with T1D were recruited to a 6-month randomised, double-blind, placebo-controlled trial. Subjects received either 3.3 g/day of encapsulated n-3PUFA or encapsulated 3.0 g/day corn oil placebo (PLA) for 6-months, with follow-up at 9-months after 3-month washout. Erythrocyte fatty acid composition was determined via gas chromatography. Endpoints included inflammation-associated endothelial biomarkers (vascular cell adhesion molecule-1 [VCAM-1], intercellular adhesion molecule-1 [ICAM-1], E-selectin, P-selectin, pentraxin-3, vascular endothelial growth factor [VEGF]), and their mediator tumor necrosis factor alpha [TNFα] analysed via immunoassay, vascular structure (carotid intima-media thickness [CIMT]) and function (brachial artery flow mediated dilation [FMD]) determined via ultrasound technique, blood pressure, glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial metabolism. Results Twenty subjects completed the trial in full. In the n-3PUFA group, the mean ± SD baseline n-3PUFA index of 4.93 ± 0.94% increased to 7.67 ± 1.86% ( P < 0.001) after 3-months, and 8.29 ± 1.45% ( P < 0.001) after 6-months. Total exposure to n-3PUFA over the 6-months (area under the curve) was 14.27 ± 3.05% per month under n-3PUFA, and 9.11 ± 2.74% per month under PLA ( P < 0.001). VCAM-1, ICAM-1, E-selectin, P-selectin, pentraxin-3, VEGF, TNFα, CIMT, FMD, blood pressure, HbA1c, FPG, and postprandial metabolism did not differ between or within groups after treatment ( P > 0.05). Conclusions This study indicates that daily high-dose-bolus of n-3PUFA supplementation for 6-months does not improve vascular health, glucose homeostasis, or metabolic parameters in subjects with T1D. The findings from this preliminary RCT do not support the use of therapeutic n-3PUFA supplementation in the treatment and management of T1D and its associated complications. Trial Registration ISRCTN, ISRCTN40811115. Registered 27 June 2017, http://www.isrctn.com/ISRCTN40811115 ." @default.
• W3048930036 created "2020-08-18" @default.
• W3048930036 creator A5021428860 @default.
• W3048930036 creator A5023762401 @default.
• W3048930036 creator A5024134135 @default.
• W3048930036 creator A5035284985 @default.
• W3048930036 creator A5042245860 @default.
• W3048930036 creator A5045777979 @default.
• W3048930036 creator A5050807000 @default.
• W3048930036 creator A5061789378 @default.
• W3048930036 creator A5063996717 @default.
• W3048930036 creator A5073292597 @default.
• W3048930036 creator A5083165397 @default.
• W3048930036 creator A5086223086 @default.
• W3048930036 date "2020-08-12" @default.
• W3048930036 modified "2023-10-18" @default.
• W3048930036 title "Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial" @default.
• W3048930036 cites W1511998280 @default.
• W3048930036 cites W1561671170 @default.
• W3048930036 cites W1588989558 @default.
• W3048930036 cites W1634842036 @default.
• W3048930036 cites W1907579612 @default.
• W3048930036 cites W1984756098 @default.
• W3048930036 cites W1989000544 @default.
• W3048930036 cites W1990049882 @default.
• W3048930036 cites W2004479442 @default.
• W3048930036 cites W2028647804 @default.
• W3048930036 cites W2032561352 @default.
• W3048930036 cites W2038772599 @default.
• W3048930036 cites W2039487960 @default.
• W3048930036 cites W2052211531 @default.
• W3048930036 cites W2052620776 @default.
• W3048930036 cites W2077153457 @default.
• W3048930036 cites W2082262509 @default.
• W3048930036 cites W2087484885 @default.
• W3048930036 cites W2088130406 @default.
• W3048930036 cites W2088985640 @default.
• W3048930036 cites W2097034682 @default.
• W3048930036 cites W2108602772 @default.
• W3048930036 cites W2117332151 @default.
• W3048930036 cites W2118270134 @default.
• W3048930036 cites W2122588058 @default.
• W3048930036 cites W2126039851 @default.
• W3048930036 cites W2127303044 @default.
• W3048930036 cites W2138703255 @default.
• W3048930036 cites W2145560652 @default.
• W3048930036 cites W2149433053 @default.
• W3048930036 cites W2159870928 @default.
• W3048930036 cites W2165571979 @default.
• W3048930036 cites W2171408342 @default.
• W3048930036 cites W2317235285 @default.
• W3048930036 cites W2332342068 @default.
• W3048930036 cites W2340325420 @default.
• W3048930036 cites W2599700534 @default.
• W3048930036 cites W2605226021 @default.
• W3048930036 cites W2623632204 @default.
• W3048930036 cites W2785975902 @default.
• W3048930036 cites W2793787049 @default.
• W3048930036 cites W2797780806 @default.
• W3048930036 cites W2801511858 @default.
• W3048930036 cites W2818923169 @default.
• W3048930036 cites W2889162196 @default.
• W3048930036 cites W2902860320 @default.
• W3048930036 cites W2943847251 @default.
• W3048930036 cites W2945704615 @default.
• W3048930036 cites W2949091796 @default.
• W3048930036 cites W2972576455 @default.
• W3048930036 cites W2979883746 @default.
• W3048930036 doi "https://doi.org/10.1186/s12933-020-01094-5" @default.
• W3048930036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7425064" @default.
• W3048930036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32787879" @default.
• W3048930036 hasPublicationYear "2020" @default.
• W3048930036 type Work @default.
• W3048930036 sameAs 3048930036 @default.
• W3048930036 citedByCount "18" @default.
• W3048930036 countsByYear W30489300362021 @default.
• W3048930036 countsByYear W30489300362022 @default.
• W3048930036 countsByYear W30489300362023 @default.
• W3048930036 crossrefType "journal-article" @default.
• W3048930036 hasAuthorship W3048930036A5021428860 @default.
• W3048930036 hasAuthorship W3048930036A5023762401 @default.
• W3048930036 hasAuthorship W3048930036A5024134135 @default.
• W3048930036 hasAuthorship W3048930036A5035284985 @default.
• W3048930036 hasAuthorship W3048930036A5042245860 @default.
• W3048930036 hasAuthorship W3048930036A5045777979 @default.
• W3048930036 hasAuthorship W3048930036A5050807000 @default.
• W3048930036 hasAuthorship W3048930036A5061789378 @default.
• W3048930036 hasAuthorship W3048930036A5063996717 @default.
• W3048930036 hasAuthorship W3048930036A5073292597 @default.
• W3048930036 hasAuthorship W3048930036A5083165397 @default.
• W3048930036 hasAuthorship W3048930036A5086223086 @default.
• W3048930036 hasBestOaLocation W30489300361 @default.
• W3048930036 hasConcept C126322002 @default.
• W3048930036 hasConcept C134018914 @default.
• W3048930036 hasConcept C142724271 @default.
• W3048930036 hasConcept C185592680 @default.
• W3048930036 hasConcept C19038510 @default.
• W3048930036 hasConcept C204787440 @default.
• W3048930036 hasConcept C27081682 @default.
• W3048930036 hasConcept C2777180221 @default.

• next